Advarra Launches Site Identification Technology with Insights Directly from Sites

New capability pairs intelligence from Advarra's robust IRB and site source-of-truth operational systems, giving sponsors and CROs unmatched visibility into site performance

COLUMBIA, Md., Oct. 1, 2026 /PRNewswire/ -- Advarra, the market leader in IRB oversight and a leading provider of connected, intelligence-powered research technology, today announced the launch of its new Site ID technology. Part of Advarra's Site Identification & Feasibility solution, the offering gives sponsors and CROs deeper operational evidence to identify high-fit, high-performing research sites for their clinical trials.

Site selection is one of the most consequential decisions a sponsor or CRO makes in a clinical trial. While teams today already draw on a range of valuable inputs—public registries, internal study history, investigator and site surveys, and real-world data such as claims, EMR, and lab records—those inputs alone can't paint a complete picture of a site's capacity and performance. That gap carries potential uncertainty for study timelines and budgets: According to research from the Tufts Center for the Study of Drug Development, it takes an average of seven months to move a site from identification through activation, while a delayed or underperforming site can cost sponsors upwards of $25,000 in startup investment before a single patient enrolls.

Advarra's Site ID intelligence adds the missing layer, drawing on two data sources no other provider can combine at scale: eIRB-validated insights, and the clinical trial management systems used by thousands of principal investigators as their source of truth for research site operations. Powered by Braid, Advarra's data and AI platform, the solution shows how quickly a site activates, how it has performed against enrollment targets, how much competing study volume it's carrying, and how repeatable its performance is against true peers—giving study teams the clarity and conviction in their site plan to enroll the trial on time.

"As we expand our development program from Phase II into Phase III, our internal site history only takes us so far," said Cameron Szakacs, PhD, VP of drug development at Milestone Pharmaceuticals. "Advarra's Site ID gives us a credible place to start: sites with relevant cardiovascular experience, backed by data on how they've performed on studies like ours. This allows us to confidently build our site lists with an evidence-based approach."

Advarra's Site ID intelligence is available in two ways. The new self-service app gives teams always-on access to explore, compare, and export site intelligence, while the service remains available for teams who want Advarra experts to deliver the same intelligence per study, with no software commitment.

Travis Caudill, VP, feasibility & site selection at ICON, commented: "Advarra's Site ID app adds a valuable layer of real-time intelligence, allowing our teams to evaluate startup speed, enrollment history, and current study load, and see how a site candidate compares to others running similar studies. It strengthens the evidence available to support informed site selection decisions."

"Site identification starts with a straightforward question: 'Which sites should we consider for this study?' But real confidence comes from answering the deeper questions that follow: 'How will this site perform, and can we count on it to deliver?'" added Ashley Davidson, SVP, head of product at Advarra. "Advarra's Site ID gives sponsors and CROs that evidence upstream, so they can focus on well-matched sites from the start. The result: fewer surveys for sites to complete, and less time spent confirming what the data already shows."

To learn more, visit the Site Identification & Feasibility solution page on Advarra's website.

About Advarra

Advarra provides the platform, insights, and expertise that make clinical trials more efficient and connected. As the leading independent IRB, we bring more than 40 years of trusted oversight to the industry, setting the standard for ethical reviews while building the largest collection of digitized protocols and operational data. This combined intelligence guides the protocol's entire journey—from design through review, activation, and conduct—fueling a smarter, more adaptive research ecosystem.

Backed by decades of partnership with research sites, Advarra delivers the core systems and services that 50,000 investigators and their study teams depend on for optimal trial operations. Integrated with our solutions for study design, startup, and conduct, these capabilities create a collaborative technology platform trusted by sponsors and CROs globally.

By designing AI-powered workflows that streamline operations, reduce administrative burden, and promote transparency for all study stakeholders, we're reimagining what's possible in clinical research. Learn more at www.advarra.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/advarra-launches-site-identification-technology-with-insights-directly-from-sites-302895902.html

SOURCE Advarra